Features | Partner Sites | Information | LinkXpress
Sign In
PZ HTL SA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Discovery Provides Insight into Fundamental Mystery of Fetal-Maternal Immune Tolerance

By BiotechDaily International staff writers
Posted on 21 Jun 2012
Scientists for the first time have discovered key steps in the molecular mechanisms involved in preventing the immune system of pregnant mammals from rejecting fetal tissue as foreign. The findings may also provide leads to better understanding and treatment of medical conditions arising from abnormalities in this and similar immune system pathways.

Although the foreign antigens of the developing fetus and of the placenta come into direct contact with cells of the maternal immune system, they fail to evoke the typical rejection response seen with organ transplant tissue and pathogens. Previous findings by researchers at New York University School of Medicine (New York City, NY, USA) prompted them to ask if there was some sort of barrier preventing activated T cells from reaching the fetus. They turned their attention to studying properties of the decidua and there, in a mouse model, they found new answers. The research team has now discovered that the onset of pregnancy causes the genes responsible for recruiting immune cells to sites of inflammation to be turned off within the decidua. As a result, T cells are not able to accumulate inside the decidua and therefore do not attack the fetus and placenta. Specifically, the implantation of an embryo changes the packaging of certain chemokine genes in the nuclei of the developing decidua's stromal cells. The change in the DNA packaging permanently silences (deactivates) the chemokine genes. Consequently, the chemokines are not expressed and T cells are not recruited to the site of embryo implantation.

Also of note, the observed change in the DNA packaging occurred by epigenetic modification, a modification that changes gene expression but not due to a hereditable gene mutation. So the findings also reveal “epigenetic modification of chemokine genes within tissue stromal cells as a modality for limiting the trafficking of activated T cells," said lead investigator Adrian Erlebacher, MD, PhD, associate professor of pathology at NYU School of Medicine and member of the NYU Cancer Institute at NYU Langone Medical Center. "It turns out that the cells that typically secrete the chemoattractants to bring the T cells to sites of inflammation are inhibited from doing so in the context of the pregnant uterus. The decidua appears instead as a zone of relative immunological inactivity," he explained.

Prof. Erlebacher and his team will next investigate whether these modifications are also present within the human decidua and whether the failure to generate them appropriately is associated with complications of human pregnancy. In addition to pregnancy, the study’s findings could also have medical implications for organ transplantation, autoimmune diseases, and even cancer since they also raise the possibility that the same kind of mechanism could enhance a tumor's ability to survive inside its host.

Related Links:
New York University School of Medicine


comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.